The impact of immunosuppression despite virological suppression (immuno-virological discordance, ID) on the risk of developing fatal and non-fatal AIDS/non-AIDS events is unclear and remains to be elucidated.
Patients in EuroSIDA starting at least 1 new antiretroviral drug with CD4<350 cells/µl and viral load (VL)>500 copies/mL were followed-up from the first day of VL< = 50 copies/ml until a new fatal/non-fatal non-AIDS/AIDS event. Considered non-AIDS events included non-AIDS malignancies, pancreatitis, severe liver disease with hepatic encephalopathy (>grade 3), cardio- and cerebrovascular events, and end-stage renal disease. Patients were classified over time according to whether current CD4 count was above (non-ID) or below (ID) baseline level. Relative rates (RR) of events were calculated for ID vs. non-ID using adjusted Poisson regression models.
2,913 patients contributed 11,491 person-years for the analysis of non-AIDS. 241 pre-specified non-AIDS events (including 84 deaths) and 89 AIDS events (including 10 deaths) occurred. The RR of developing pre-specified non-AIDS events for ID vs. non-ID was 1.96 (95% CI 1.37–2.81, p<0.001) in unadjusted analysis and 1.43 (0.94–2.17, p = 0.095) after controlling for current CD4 count. ID was not associated with the risk of AIDS events (aRR 0.76, 95% CI 0.41–1.38, p = 0.361).
Citation: Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, et al. (2014) Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. PLoS ONE 9(1): e87160. doi:10.1371/journal.pone.0087160
Editor: Dimitrios Paraskevis, University of Athens, Medical School, Greece
Received: September 7, 2013; Accepted: December 19, 2013; Published: January 31, 2014
Copyright: © 2014 Zoufaly et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Primary support is provided by the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773), the 6th Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/2007–2013, EuroCoord no. 260694) programmes. Current support also includes unrestricted grants by Gilead, Pfizer, and Merck and Co. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787). AZ received a grant from MSD SHARP & DOHME GmbH for the performance of this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Primary support is provided by the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773), the 6th Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/2007–2013, EuroCoord no. 260694) programmes. Current support also includes unrestricted grants by Gilead, Pfizer, and Merck and Co. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787). AZ received a grant from MSD SHARP & DOHME GmbH for the performance of this research. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Combination antiretroviral therapy (cART) mainly exerts its effect on the reduction of HIV related morbidity and mortality by suppressing HIV viral load which leads to an increase of CD4 cells , . A rapid increase of CD4 cells is important in the light of the fact that a significant proportion of patients continue to present for therapy when advanced immunodeficiency is present and their immediate risk of AIDS and death is high . The majority of patients achieve a sustained reconstitution of CD4 cells upon starting cART  although blunted CD4 responses do also occur in patients initiating when their CD4 count was <200 cells/µl , , . The inability to achieve an increase in CD4 count in the context of sustained virological suppression is also known as immuno-virological discordance (ID)  and has been associated with increased mortality . Indeed, previous work from the ClinSurv Study group showed an association between ID and the risk of AIDS and death . However, this risk was greatly reduced with longer time spent with a suppressed viral load suggesting that maintaining a suppressed viral load is key for patients with immuno-virological discordance . Previous data indicate that non-AIDS events are nowadays important contributors to HIV associated morbidity and mortality and that current CD4 is also a predictor of these events . The role of immuno-virological discordance to predict the risk of fatal and non-fatal non-AIDS and AIDS events remains unclear and was evaluated in this analysis. The aim of our analysis was to investigate whether a lack of any increase in CD4 count above levels observed prior to starting a suppressive regimen and despite evidence of sustained viral suppression was associated with adverse clinical progression.
The EuroSIDA study is a prospective, observational cohort study including HIV-1 infected patients from 31 European countries as well as Israel and Argentina .
To date, nine cohorts have been enrolled starting in May 1994. At enrollment, demographic characteristics and clinical information are obtained. Every 6 months CD4 count and viral load data as well as data on antiretroviral drugs used are collected in a standardized report form and forwarded to the coordinating center. The pre-specified non-AIDS events included are those used in previous EuroSIDA publications on this topic  and the expert opinion of members of the steering committee as events which are likely to have a major impact of HIV associated morbidity and mortality. These data have been routinely collected since January 2001 and include non-AIDS malignancies, pancreatitis, severe liver disease with hepatic encephalopathy (grade 3 or 4), cardio- and cerebrovascular events (i.e. myocardial infarction, placement of coronary artery bypass graft or angioplasty, carotid endarterectomy, stroke), and end-stage renal disease. Death from all causes except for AIDS related conditions was counted as non-AIDS defining. Diagnoses of AIDS are recorded using the clinical 1993 CDC definition  and causes of deaths are categorized using the Coding Cause of Death in HIV (CoDe) classification . Members of the coordinating office visit all centers at least once a year to ensure correct patient selection and to verify that data are accurate. In patients with a clinical event, all entered data are checked against case files and 10% of case files are checked in all other patients.
Each of the centers participating in EuroSIDA sought ethical clearance according to local regulations and laws and patients gave their informed consent to take part in the study. All data were anonymized prior to statistical analysis. The senior investigator at each clinical site is responsible for obtaining and maintaining this/these approval(s) at all times during the conduct of the study. Full study details are available at www.cphiv.dk.
Patients in the cohort with a CD4 count of less than 350 cells/µl who after 1 January 2001 started at least one new antiretroviral drug with most recent viral load >500 copies/mL (either because starting their first cART or because switching drugs after failing on their previous regimen) and subsequently achieved viral suppression < = 50 copies/mL were included. Follow-up accrued from the first day of viral suppression below 50 copies/mL following the initiation of the new regimen (baseline) until the first of either a fatal or non-fatal non-AIDS or AIDS event, viral rebound >50 copies/mL (defined as the time of the first of 2 consecutive values above this threshold) or patients’ latest available follow-up visit in which they were known to be still event-free. Each AIDS and non-AIDS condition which developed during follow-up was counted as one event and recurrences of the same condition were not counted.
Data were left-censored at entry in the cohort and patients had to have at least one month of prospective follow-up after baseline to be included. CD4 counts were carried forward until a new CD4 test was performed.
Immuno-virological response was defined using both the CD4 count measured prior to initiation of the suppressive regimen and the current CD4 count. In particular if patients’ current CD4 count was still equal or below the pre-ART initiation level then the person was defined as immuno-virological discordant (ID) at the time of the current CD4 count measure. In contrast, any current rise in CD4 count above pre-ART level would reverse his/her classification to immunological responder (non-ID). Rates of fatal and non-fatal non-AIDS and AIDS events were calculated over 6 monthly periods (0–6, 7–12, 13–18, 19–24, >24 months) of virological suppression after baseline and stratified according to ID status. Univariable and multivariable Poisson regression models were performed to estimate the risk associated with a current ID status (fitted as a time-dependent covariate). When exploring the magnitude of the risk associated with being ID over time, a categorical covariate grouping periods of follow-up with thresholds 0–6, 7–12, 13–18, 19–24, >24 months and using the 0–6 months period as the comparator group was included in the model. Other potential risk factors or confounders which were considered for inclusion in the model were: age, hepatitis C serostatus, mode of HIV transmission, race, cohort of origin, the number of previous ART regimens used, current CD4 count (or baseline CD4 count in an alternative model) and specific antiretroviral drugs included in the newly initiated regimen.
Potential confounders were selected on the basis of prior knowledge and when hypothesized to be common causes of both the exposure of interest and the risk of developing the outcome. A software based on directed acyclic graphs  was employed to identify the appropriate model to correctly estimate the direct effect of ID condition on the risk of the outcomes.
To be consistent with previous analysis of the data of the cohort, current CD4 count was fitted on a log2 scale as this was shown to improve the goodness of fit of the model. Models also included time from initiation of new regimen to viral suppression, current or previous smoking, history of impaired renal function at baseline (defined as an estimated Cockroft-Gault glomerular filtration rate <60 mg/dL/1.73 m2), anaemia (defined as haemoglobin levels <14 mg/dl in males and <12 mg/dl in females), diabetes (defined as having previously started any antidiabetic treatment or diagnosis of insulin dependent diabetes), and hypertension (defined as a systolic/diastolic blood pressure> = 140/> = 90 mmHg mmHg or previous initiation of any antihypertensive treatment).
Separate analyses were performed for two endpoints (fatal and non-fatal non-AIDS, and fatal and non-fatal AIDS) using a competing risk approach (i.e. by truncating follow-up at July 01, 2011 instead of the date at which a competing event occurred). In brief, the competing event (e.g. a non-AIDS event in the case of a cause specific analysis with an AIDS event as endpoint) was removed to avoid overestimation of the cumulative probability of AIDS events . The cause of death was used to define the non-AIDS (only deaths from any cause that were unrelated to AIDS are included) and AIDS (only deaths from AIDS related causes are included) endpoints. We assumed that deaths due to other reasons (e.g. suicide) did not have an indirect effect on the probability to develop AIDS or other non-AIDS co-morbidities and therefore patients’ follow-up was censored at the date of death for these reasons. Of note, because we adopted combined endpoint such as ‘AIDS events’ the issue of competing risk of developing, say, a PCP prior to a diagnosis of, say, Kaposi sarcoma is automatically removed. For the non-AIDS endpoint we performed sensitivity analyses in the subsets of patients who were treatment-naïve when they started the new baseline regimen and of those who achieved complete viral suppression within a maximum of 1 year after starting the new baseline regimen. The latter analysis aimed at reducing potential bias introduced by participants who may have experienced adherence or tolerability issues on the newly started regimen. In a further sensitivity analysis we modified the main inclusion criterion by including patients who started the new regimen with a CD4 count <200 cells/µl (instead of 350) and consequently used this lower cut-off for the definition of time-dependent immuno-virological discordance.
The likelihood ratio test was used to test temporal trends and, more in general, to compare the difference in goodness of fit of nested models (for example models with or without specific interaction terms). STATA v12.1 was used for all analyses. All p-values were two sided and a value of <0.05 was considered significant unless it was a subgroup analysis for which we required the p-value to be smaller than 0.05/k where k was the total number of identified groups (Bonferroni correction).
A total of 2,913 patients satisfied the inclusion criteria for this analysis (Figure 1). Median age was 42 (range 20–82) years. Seventy two percent of patients were male and the most common transmission risk was men having sex with men (38%). At time of initiation of the new regimen the majority of patients (55%) had a CD4 count of 200–350 cells/µl and 25% had never previously received antiretroviral treatment. One third of patients (33%) had experienced clinical AIDS prior to starting the new regimen. These and other characteristics of patients at initiation of the new regimen (baseline) are shown in Table 1.
Fatal and Non-fatal Non-AIDS
For the primary endpoint, fatal and non-fatal non-AIDS, 11,491 person years of follow-up were available and 241 events including 157 non-AIDS disease events and 84 non-AIDS deaths occurred. Malignancies classified as not AIDS related were the most common disease events (n = 72, 46%) followed by cerebrovascular diseases (n = 46, 39%). Kaplan Meier estimate of median survival time in patients who died was 2.1 (95% CI 1.6–2.8) years. Malignancies (n = 23, 27%) were also the most common causes of death. 42 (17%) fatal or non-fatal non-AIDS events occurred in ID patients (rate 53/1,000PYFU [95% CI 38–72]) vs. 199 (83%) in patients without ID (rate 19/1,000PYFU [95% CI 16–21]) p<0.001 (Figure 2).
In the adjusted Poisson regression analysis including demographic and clinical parameters (Table 2; model 1) the risk of fatal and non-fatal non-AIDS was almost two-fold higher in patients currently classified as ID compared to those classified as non-ID (aRR 1.96, 95% CI 1.37–2.81, p<0.001) Point estimates were slightly lower in a model adjusted for demographic factors as well as baseline CD4 count (Table2; model 2). After adjusting for current CD4, only a tendency for an association between ID and the risk of non-AIDS remained (aRR 1.43, 95% CI 0.94–2.17,p = 0.095).
Compared to the first 6 months of viral suppression (reference group), the adjusted relative rate of experiencing fatal or non-fatal non-AIDS for patients classified as ID was 1.06 (95% CI 0.32–3.50) in month 7–12, 0.81 (95% CI 0.23–2.81) in month 13–18, 1.67 (95% CI 0.51–5.41) in month 19–24 and 0.91 (95% CI 0.23–3.60) thereafter, test for trend p = 1.00). Similarly, there was no tendency for a decline in risk in periods in which patients were classified as non-ID (month 7–12: aRR 0.97, 95% CI 0.55–1.72, month 13–18 aRR 1.25, 95% CI 0.71–2.18, month 19–24 aRR 0.59, 95% CI 0.28–1.23, and >24 months aRR 1.14, 95% CI 0.63–2.07, p-value for test of trend = 0.24).
Factors besides ID and current CD4 count significantly associated with the risk of developing the composite endpoint in the main analysis included older age, a diagnosis of anaemia prior to baseline, previous non-AIDS, and current use of antiretroviral treatment consisting of less than 3 drugs (Table 3).
Sensitivity Analyses for the Non-AIDS Endpoint
The association between ID and the risk of non-AIDS events appeared to be higher in patients who were therapy-naïve (aRR = 3.06, 95% CI 0.69–13.55) vs. those who were treatment experienced (aRR = 1.30, 95% CI 0.84–2.02) at baseline, although there was no evidence of interaction (p-value = 0.583).
After restricting our analysis to patients who achieved viral suppression within one year after initiation of cART (n = 1,489, 51% of total follow-up for 6,333 person years and 162 events), the association between ID and the risk of developing non-AIDS events (aRR 1.63, 95% CI 0.95–2.78, p = 0.073) was consistent with that found in the main analysis. In a sub-analysis of ART naïve patients who achieved complete virological suppression within one year (21 events only), ID was marginally significantly associated with non-AIDS even after controlling for current CD4 (aRR for ID 4.54, 95% CI 0.97–21.2, p = 0.054).
Results were similar in a sensitivity analysis defining virological failure as one viral load >50 regardless of confirmation (data not shown).
In the analysis using the alternative cut-off of 200 CD4 cells/µl (n = 1,349, 170 events, 5247 PYFU), results were also similar: aRR 2.39, 95% CI 1.37–4.18, p = 0.002) in the model adjusted only for demographic and clinical factors and aRR 1.58, 95% CI 0.81–3.12, p = 0.183) after further controlling for current CD4 count.
Fatal and Non-fatal AIDS
In the separate analysis with AIDS as an endpoint, 11,723 person years of follow-up were available. A total of 89 AIDS events including 10 AIDS-related deaths occurred. Oesophageal candidiasis was a frequently observed opportunistic infection (n = 15, 17%) followed by pulmonary and extrapulmonary tuberculosis (14 patients, 16%). Kaplan Meier estimate of median survival time in patients who died was 1.3 (95% CI 0.3–2.0) years. AIDS malignancies were the most common cause (n = 8, 80%).
ID was significantly associated with the risk of developing AIDS-related events when adjusted for demographic and clinical factors only (aRR 1.86, 95% CI 1.07–3.23, p = 0.03). However, after adjusting for current CD4 count, ID was no longer independently associated (aRR 0.76, 95% CI 0.41–1.38, p = 0.36). Factors significantly associated with the risk of developing AIDS included current CD4 (aRR 0.50 per doubling of the count, 95% CI 0.40–0.62, p<0.001), diagnosis of anaemia at baseline (aRR 2.21, 95% CI 1.46–3.35, p<0.001), and a previous AIDS condition (different from that observed in follow-up, aRR 2.07, 95% CI 1.33–3.20, p = 0.001).
In our analysis, we found that people who failed to achieve a CD4 count above the level present at the time of starting a new regimen, despite having achieved and maintained viral suppression <50 copies/mL on ART, tended to have an increased risk of developing non-AIDS morbidity and mortality. Because of the wide confidence interval around our estimate, our results may be considered inconclusive. However, a two-fold increased risk in people with ID cannot be excluded. Our results should guide further investigations using larger study populations to test whether the lack of statistical significance was due to limited power of our analysis. Of note, the association was independent of demographic characteristics and baseline CD4 count but seemed to be mainly explained by a low current CD4 count. There was a small residual independent effect but only in people who started the new regimen when they were ART-naïve and who achieve virological suppression within one year. In additions, there was no evidence for a decreasing risk of non-AIDS events with longer time with a viral load < = 50 copies/mL in people with or without ID.
Our data suggest that in order to reduce the risk of non-AIDS events in people starting therapy with a CD4<350 cells/µl, continuous monitoring for difference between current CD4 count and the level registered at the time of initiation of a new regimen may be considered starting as early as the first 6 months following viral suppression. The cut-off of 350 CD4 cells/µl as baseline was chosen as this represents the threshold below which cART is generally recommended. However, also when the alternative cut-off of 200 CD4 cells/µl was used, our results were similar although the analyses had reduced statistical power.
In a previous analysis, ID was associated with a higher risk of AIDS and death . However, this analysis was unadjusted for current CD4 count and only included patients initiating their first cART from ART-naïve at <200 CD4 cells/µl in a cohort in Germany. Because of the different inclusion criteria as well different definitions of ID patients, results cannot be directly compared.
Previous analyses of EuroSIDA data demonstrated that current CD4 count is a significant predictor of the risk of non-AIDS events although the association was less strong than that found for AIDS events , . More specifically, it was previously shown, that those with a current CD4 count of <200 cells/µl and with suppressed viraemia on cART have lower rates of AIDS and, to a lesser extent, non-AIDS events compared to patients with ongoing viral replication . The potential independent role of ID had not been investigated in this analysis.
In the present study we included time-updated current CD4 count and immuno-virological discordance status, because we hypothesized that the risk associated with the incapacity to reconstitute CD4 cells over time may not be fully captured by current CD4 count without taking into account the status of immunosuppression observed prior to starting the suppressive regimen. A similar approach was also used in a recent study by Lapadula et al who, however, used a different definition of non-AIDS events but a similar definition of ID patients and found a strong association between lack of CD4 count recovery on suppressive ART and risk of developing the composite endpoint of AIDS and non-AIDS events .
The finding for non-AIDS events is intriguing as it suggests that patients’ current status of immunodeficiency is not able to fully explain why some people remain at higher risk of clinical complications. However, this needs to be confirmed in further analyses as measurement variability in CD4 tests and differences in frequencies of measurement may be alternative explanations.
Indeed, it is possible that ID is a marker of one of more unmeasured factors that put these people at increased risk of an adverse clinical outcome. For example, immuno-virological discordance may be the effect of incomplete bone marrow or thymus output as well as excessive destruction or disturbed immunoregulation.  In addition, lymph node fibrosis could contribute to persistent low CD4 counts.  Furthermore, higher mortality rates were recently observed in parents of immunological non-responders suggesting that genetic factors may be involved as well . In patients with low CD4 counts but suppressed viraemia higher rates of cellular immune activation markers including CD38 and HLA-DR together with higher cell-associated HIV-RNA have been observed and this has been linked particularly to non-AIDS morbidity and mortality . The higher immune activation may set the stage for non-AIDS events including cardiovascular disease . Furthermore, non-AIDS malignancies have been strongly linked with HIV induced immunodeficiency , . In our analysis, we failed to show an effect of ID which was independent of current CD4 count. This can be due to lack of power or characteristics of the study population included. Indeed, when restricting to fully adherent persons who started a new regimen from ART-naïve we obtained stronger evidence for an independent effect. Of note, in contrast, there was no significant association between ID status and the risk of AIDS events.
Our study has some limitations: first, the non-AIDS conditions considered here as endpoint-defining events represent a subset of non-AIDS events causing HIV morbidity. However, this selection has been previously used . Second, based on our restrictive inclusion criteria, the numbers of people with an event is quite low and we were not able to investigate the risk associated with specific groups of conditions separately (for example we could hypothesize that the risk associated with being ID varies by specific malignancy). In addition, it was not possible to obtain robust estimates of the event rates after 24 months from baseline in the ID group due to the low number of patients remaining at risk after this time point.
In conclusion, patients with immuno-virological discordance, in the context of suppressed viral load appeared to be at higher risk of fatal and non-fatal non-AIDS events although most of this increased risk seems to be explained by a low current CD4 count. An independent effect was found only in the subset of ART-naïve patients who experienced a rapid virological response. Another important finding was that this increased risk, if it exists, does not seem to decrease with longer duration of viral suppression, suggesting that such patients should remain under close follow-up for change in CD4 count from pre-therapy level, also after extended periods of being on cART. If this observation is confirmed in other studies it has profound implications as it suggests that cART alone may not be able to substantially remove the risk of non-AIDS in patients identified as ID. To date, strategies to directly influence immune reconstitution by adding interleukin-2 or by modifying cART regimens have failed to show benefit over viral suppression alone , ; therefore new strategies perhaps aiming at other mechanisms to boost functional CD4 cells or decreasing the levels of immune-activation (e.g. interleukin-7, probiotics) need to be tested in people who show incomplete immune reconstitution despite sustained viral suppression.
The multi-center study group of EuroSIDA (national coordinators in parenthesis):
Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires. Austria: (N Vetter), Pulmologisches Zentrum der Stadt Wien, Vienna; R Zangerle, Medical University Innsbruck, Innsbruck. Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM Mitsura, Gomel State Medical University, Gomel; O Suetnov, Regional AIDS Centre, Svetlogorsk. Belgium: (N Clumeck), S De Wit, M Delforge, Saint-Pierre Hospital, Brussels; R Colebunders, Institute of Tropical Medicine, Antwerp; L Vandekerckhove, University Ziekenhuis Gent, Gent. Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta Sarajevo, Sarajevo. Bulgaria: (K Kostov), Infectious Diseases Hospital, Sofia. Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb. Czech Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles University Hospital, Plzen. Denmark: (J Nielsen), G Kronborg,T Benfield, M Larsen, Hvidovre Hospital, Copenhagen; J Gerstoft, T Katzenstein, A–B E Hansen, P Skinhøj, Rigshospitalet, Copenhagen; C Pedersen, Odense University Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus. Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakkusosakond Siseklinik, Kohtla-Järve. Finland: (M Ristola), Helsinki University Central Hospital, Helsinki. France: (C Katlama), Hôpital de la Pitié-Salpétière, Paris; J–P Viard, Hôpital Necker-Enfants Malades, Paris; P–M Girard, Hospital Saint-Antoine, Paris; JM Livrozet, Hôpital Edouard Herriot, Lyon; P Vanhems, University Claude Bernard, Lyon; C Pradier, Hôpital de l’Archet, Nice; F Dabis, D Neau, Unité INSERM, Bordeaux. Germany: (J Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule Hannover; J van Lunzen, O Degen, University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; S Staszewski, JW Goethe University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität Köln, Cologne. Greece: (J Kosmidis), P Gargalianos, G Xylomenos, J Perdios, Athens General Hospital; G Panos, A Filandras, E Karabatsaki, 1st IKA Hospital; H Sambatakou, Ippokration Genereal Hospital, Athens. Hungary: (D Banhegyi), Szent Lásló Hospital, Budapest. Ireland: (F Mulcahy), St. James’s Hospital, Dublin. Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; S Pollack, G Hassoun, Rambam Medical Center, Haifa; S Maayan, Hadassah University Hospital, Jerusalem. Italy: (S Vella), Istituto Superiore di Sanità, Rome; R Esposito, I Mazeu, C Mussini, Università Modena, Modena; C rici, Ospedale Riuniti, Bergamo; R Pristera, Ospedale Generale Regionale, Bolzano; F Mazzotta, A Gabbuti, Ospedale S Maria Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; A Chirianni, E Montesarchio, M Gargiulo, Presidio Ospedaliero AD Cotugno, Monaldi Hospital, Napoli; G Antonucci, A Testa, G D’Offizi, C Vlassi, M Zaccarelli, A Antorini, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan; A d’Arminio Monforte, Istituto Di Clinica Malattie Infettive e Tropicale, Milan. Latvia: (B Rozentale), I Zeltina, Infectology Centre of Latvia, Riga. Lithuania: (S Chaplinskas), Lithuanian AIDS Centre, Vilnius. Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, Luxembourg. Netherlands: (P Reiss), Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam. Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, Oslo. Poland: (B Knysz) J Gasiorowski, Medical University, Wroclaw; A Horban, E Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; A Grzeszczuk, R Flisiak, Medical University, Bialystok; A Boron-Kaczmarska, M Pynka, M Parczewski, Medical Univesity, Szczecin; M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; H Trocha, Medical University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz. Portugal: (F Antunes), M Doroana, L Caldeira, Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon. Romania: (D Duiculescu), Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, Bucarest. Russia: (A Rakhmanova), Medical Academy Botkin Hospital, St Petersburg; N Zakharova, St Petersburg AIDS Centre, St Peterburg; S Buzunova, Novgorod Centre for AIDS, Novgorod. Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade. Slovakia: (M Mokráš), D Staneková, Dérer Hospital, Bratislava. Slovenia: (J Tomazic), University Clinical Centre Ljubljana, Ljubljana. Spain: (J González-Lahoz), V Soriano, P Labarga, J Medrano, Hospital Carlos III, Madrid; S Moreno, J. M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; JM Gatell, JM Miró, Hospital Clinic i Provincial, Barcelona; P Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, Barcelona. Sweden: (A Blaxhult), Venhaelsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö University Hospital, Malmö. Switzerland: (B Ledergerber), R Weber, University Hospital, Zürich; P Francioli, M Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne; B Hirschel, E Boffi, Hospital Cantonal Universitaire de Geneve, Geneve; H Furrer, Inselspital Bern, Bern; M Battegay, L Elzi, University Hospital Basel. Ukraine: (E Kravchenko), N Chentsova, Kiev Centre for AIDS, Kiev; V Frolov, G Kutsyna, Luhansk State Medical University; Luhansk; S Servitskiy, Odessa Region AIDS Center, Odessa; M Krasnov, Kharkov State Medical University, Kharkov. United Kingdom: (S Barton), St. Stephen’s Clinic, Chelsea and Westminster Hospital, London; AM Johnson, D Mercey, Royal Free and University College London Medical School, London (University College Campus); A Phillips, MA Johnson, A Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); M Murphy, Medical College of Saint Bartholomew’s Hospital, London; J Weber, G Scullard, Imperial College School of Medicine at St. Mary’s, London; M Fisher, Royal Sussex County Hospital, Brighton; C Leen, Western General Hospital, Edinburgh.
Steering Committee: J Gatell, B Gazzard, A Horban, I Karpov, B Ledergerber, M Losso, A D’Arminio Monforte, C Pedersen, A Rakhmanova, M Ristola, J Rockstroh (Chair), S De Wit (Vice-Chair) Additional voting members: J Lundgren, A Phillips, P Reiss.
Coordinating Centre Staff: O Kirk, A Mocroft, A Cozzi-Lepri, D Grint, D Podlekareva, J Kjær, L Peters, J Nielsen, J Tverland, D Raben, A H Fischer, A Schultze, L Shepherd.
EuroSIDA representatives to EuroCoord: O. Kirk, A. Mocroft, J. Grarup, P. Reiss, A. Cozzi-Lepri, R. Thiebaut, J. Rockstroh, D. Burger, R. Paredes, J. Kjær. L. Peters.
Analyzed the data: AZ ACL JR. Contributed reagents/materials/analysis tools: AZ ACL JR OK PR JDL DJ LM RZ AM JVL. Wrote the paper: AZ ACL JR OK PR JDL DJ LM RZ AM JVL.
- 1. Hughes MD, Daniels MJ, Fischl MA, Kim S (1998) Schooley RT (1998) CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 12: 1823–1832.
- 2. Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, et al. (1999) Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 13: 951–956.
- 3. Wolbers M, Bucher HC, Furrer H, Rickenbach M, Cavassini M, et al. (2008) Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med 9: 397–405.
- 4. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, et al. (2007) Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370: 407–413.
- 5. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, et al. (2009) Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 48: 787–794.
- 6. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, et al. (2009) Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 48: 350–361.
- 7. Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, et al. (1999) Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 130: 570–577.
- 8. Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, et al. (2008) Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 47: 553–558.
- 9. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, et al. (2005) Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 40: 288–293.
- 10. Zoufaly A, an der Heiden M, Kollan C, Bogner JR, Fatkenheuer G, et al. (2011) Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis 203: 364–371.
- 11. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, et al. (2010) Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 55: 262–270.
- 12. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352: 1725–1730.
- 13. revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 17: 1–19.
- 14. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, et al. (2011) A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clin Trials 12: 109–117.
- 15. Shrier I, Platt RW (2008) Reducing bias through directed acyclic graphs. BMC Med Res Methodol 8: 70.
- 16. Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, et al. (2002) Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 31: 951–958.
- 17. Moore RD, Gebo KA, Lucas GM, Keruly JC (2008) Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 47: 1102–1104.
- 18. Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, et al. (2012) The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. Antivir Ther.
- 19. Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, et al. (2013) Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment AIDS. 27: 769–779.
- 20. Gazzola L, Tincati C, Bellistri GM, Monforte A, Marchetti G (2009) The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 48: 328–337.
- 21. Nies-Kraske E, Schacker TW, Condoluci D, Orenstein J, Brenchley J, et al. (2009) Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis 199: 1648–1656.
- 22. Helleberg M, Kronborg G, Larsen C, Pedersen G, Pedersen C, et al. (2013) Poor CD4 response despite viral suppression is associated with increased non-AIDS-related mortality among HIV patients and their parents. AIDS 27: 1021–1026.
- 23. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, et al. (2012) Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T cells. J Infect Dis.
- 24. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, et al. (2009) Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 23: 1059–1067.
- 25. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, et al. (2008) HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 22: 2143–2153.
- 26. Kesselring A, Gras L, Smit C, van Twillert G, Verbon A, et al. (2011) Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 52: 1458–1465.
- 27. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, et al. (2009) Interleukin-2 therapy in patients with HIV infection. N Engl J Med 361: 1548–1559.
- 28. Lanzafame M, Lattuada E, Vento S (2009) Maraviroc and CD4+ cell count recovery in patients with virologic suppression and blunted CD4+ cell response. AIDS 27: 869.